Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials

Hormonal therapies for receptor positive-breast and prostate cancer patients have shown clinical efficacy but also several side effects including osteoporosis, loss of bone mass and increased fracture risk. Denosumab represents an anti RANKL (receptor activator of nuclear factor-kB ligand) monoclona...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Bone Oncol
Glavni autori: Galvano, Antonio, Scaturro, Dalila, Badalamenti, Giuseppe, Incorvaia, Lorena, Rizzo, Sergio, Castellana, Luisa, Cusenza, Stefania, Cutaia, Sofia, Santini, Daniele, Guadagni, Fiorella, Roselli, Mario, Gori, Stefania, Latteri, Mario Adelfio, Bazan, Viviana, Giulia, Letizia Mauro, Russo, Antonio
Format: Artigo
Jezik:Inglês
Izdano: Elsevier 2019
Teme:
Review Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6700425/
https://ncbi.nlm.nih.gov/pubmed/31440444
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jbo.2019.100252
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items